Trial Profile
A exploratory Study of Apatinib and Gefitinib First-line treatment in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Mar 2017
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Mar 2017 New trial record